COCRYSTAL PHARMA NEW O.N.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more
COCRYSTAL PHARMA NEW O.N. (8CC) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, COCRYSTAL PHARMA NEW O.N. (8CC) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
COCRYSTAL PHARMA NEW O.N. - Net Assets Trend (None–None)
This chart illustrates how COCRYSTAL PHARMA NEW O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for COCRYSTAL PHARMA NEW O.N. (None–None)
The table below shows the annual net assets of COCRYSTAL PHARMA NEW O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to COCRYSTAL PHARMA NEW O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
COCRYSTAL PHARMA NEW O.N. Competitors by Market Cap
The table below lists competitors of COCRYSTAL PHARMA NEW O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Softtech Engineers Limited
NSE:SOFTTECH
|
$8.54 Million |
|
Eksun Gida Tarim Sanayi ve Ticaret A.S.
IS:EKSUN
|
$8.54 Million |
|
HLscience Co. Ltd
KQ:239610
|
$8.54 Million |
|
Anabatic Technologies Tbk PT
JK:ATIC
|
$8.54 Million |
|
Chinyang Poly
KO:010640
|
$8.54 Million |
|
Bangkok Union Insurance Public Co. Ltd.
BK:BUI
|
$8.54 Million |
|
Highcom Ltd
AU:HCL
|
$8.53 Million |
|
Clean & Science co. Ltd
KQ:045520
|
$8.52 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in COCRYSTAL PHARMA NEW O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares COCRYSTAL PHARMA NEW O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently COCRYSTAL PHARMA NEW O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares COCRYSTAL PHARMA NEW O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| COCRYSTAL PHARMA NEW O.N. (8CC) | €- | N/A | N/A | $8.54 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |